Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
The so-called “biosame” version of Kyowa Kirin’s flagship renal anemia drug Nesp (darbepoetin alfa) has shown a rapid uptake since its August launch, but speedy switches from the originator have been within expectations, the company’s president Masashi Miyamoto says. While…
To read the full story
Related Article
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Kyowa Kirin Nets Double-Digit Growth in 1st Half, Keeps Full-Year Guidance for Nesp
August 2, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
November 26, 2018
BUSINESS
- Takara Bio Voluntary Buyout Draws 148 Employees
July 22, 2026
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…